Evidence map›Paper›PMID 33535382›Full record

ArticleAntioxidants (Basel, Switzerland)2021

Tyrosine Phosphorylation Modulates Peroxiredoxin-2 Activity in Normal and Diseased Red Cells.

Alessandro Mattè, Enrica Federti, Elena Tibaldi, Maria Luisa Di Paolo, Giovanni Bisello, Mariarita Bertoldi, Andrea Carpentieri, Pietro Pucci, Iana Iatchencko, Anand B Wilson and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Estrogen receptors, ERKFrontiers in physiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Alessandro MattèDepartment of Medicine, University of Verona and AOUI Verona, 37134 Verona, Italy.
Enrica FedertiDepartment of Medicine, University of Verona and AOUI Verona, 37134 Verona, Italy.
Elena TibaldiDepartment of Molecular Medicine, University of Padua, 35128 Padua, Italy.
Maria Luisa Di PaoloDepartment of Molecular Medicine, University of Padua, 35128 Padua, Italy.ORCID 0000-0002-2370-9333
Giovanni BiselloDepartment of Neuroscience, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-3803-9555
Mariarita BertoldiDepartment of Neuroscience, Biomedicine and Movement Sciences, Section of Biological Chemistry, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-2337-9928
Andrea CarpentieriDepartment of Chemical Sciences, University Federico II of Napoli, 80126 Napoli, Italy.
Pietro PucciDepartment of Chemical Sciences, University Federico II of Napoli, 80126 Napoli, Italy.ORCID 0000-0002-5885-1495
Iana IatchenckoDepartment of Medicine, University of Verona and AOUI Verona, 37134 Verona, Italy.
Anand B WilsonDepartment of Medicine, University of Verona and AOUI Verona, 37134 Verona, Italy.
Veronica RiccardiDepartment of Medicine, University of Verona and AOUI Verona, 37134 Verona, Italy.
Angela SicilianoDepartment of Medicine, University of Verona and AOUI Verona, 37134 Verona, Italy.
Francesco TurriniDepartment of Oncology, University of Torino, 10124 Torino, Italy.
Dae Won KimDepartment of Biomedical Sciences and Institute of Bioscience and Biotechnology, Hallym University, Chuncheon 24252, Korea.
Soo Young ChoiDepartment of Biomedical Sciences and Institute of Bioscience and Biotechnology, Hallym University, Chuncheon 24252, Korea.
Anna Maria BrunatiDepartment of Molecular Medicine, University of Padua, 35128 Padua, Italy.
Lucia De FranceschiDepartment of Medicine, University of Verona and AOUI Verona, 37134 Verona, Italy.
University of Verona · ITUniversity of Padua · ITHallym University · KRCeinge Biotecnologie Avanzate (Italy) · ITUniversity of Naples Federico II · ITUniversity of Turin · IT

Funding

Università degli Studi di Verona FUR
6 · The paper itself

Abstract

Peroxiredoxin-2 (Prx2) is the third most abundant cytoplasmic protein in red blood cells. Prx2 belongs to a well-known family of antioxidants, the peroxiredoxins (Prxs), that are widely expressed in mammalian cells. Prx2 is a typical, homodimeric, 2-Cys Prx that uses two cysteine residues to accomplish the task of detoxifying a vast range of organic peroxides, H

Indexed as

oxidationperoxiredoxin-2sickle cell diseaseSyktyrosine phosphorylation

Identifiers

PMID33535382
PMCPMC7912311
OpenAlexW3127890103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.